One is insulin, which is used by people with type 1 diabetes and those with longer-lasting type 2 diabetes. With the prolongation of the disease, the function of islet B cells gradually declines, unable to fully secrete insulin, and can only rely on exogenous insulin to lower blood sugar.
The other is a GLP-1 agonist, which stimulates insulin production, blocks glucagon production, reduces liver glycogen breakdown, delays gastric emptying, and lowers fasting blood sugar two hours after meals.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.
Privacy Policy
